The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study
| Autor: | Nick B, Tsavaris, Haralabos L, Katsoulas, Christos, Kosmas, Efstathios, Papalambros, Panayiotis, Gouveris, Nikitas, Papantoniou, Sophia, Rokana, Nicolaos, Kosmas, Margarita, Skopeliti, Ourania E, Tsitsilonis |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Tumor Necrosis Factor-alpha Interleukins Antibody-Dependent Cell Cytotoxicity Antibodies Monoclonal Granulocyte-Macrophage Colony-Stimulating Factor Enzyme-Linked Immunosorbent Assay Middle Aged Dinoprostone Drug Administration Schedule Killer Cells Natural Antibodies Monoclonal Murine-Derived Interferon-gamma Chemotherapy Adjuvant Antineoplastic Combined Chemotherapy Protocols Leukocytes Mononuclear Cytokines Humans Female Fluorouracil Colorectal Neoplasms Killer Cells Lymphokine-Activated Colectomy Aged Neoplasm Staging |
| Zdroj: | Oncology. 67(5-6) |
| ISSN: | 0030-2414 |
| Popis: | We investigated the immune profile of patients with resected Dukes' stage C colorectal cancer (CRC), receiving adjuvant therapy with edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based chemotherapy.Patients received either 5 doses of Mo17-1A over 13 weeks, or 5-FU/leucovorin, or 5-FU/levamisole over 6 and 12 months, respectively. Peripheral blood was collected postoperatively and 4 months after therapy initiation. Peripheral blood mononuclear cells were tested in the autologous mixed lymphocyte reaction (AMLR), for natural killer (NK) and lymphokine-activated killer (LAK) cell activity. Serum cytokines were quantified by ELISA.Fifty-two patients entered the study. Postoperatively, they exhibited decreased levels of interleukin (IL)-2, interferon-gamma, IL-12, granulocyte-macrophage colony-stimulating factor and IL-15, low cellular immune responses (AMLR, NK- and LAK-cytotoxicity) and increased levels of IL-1beta, tumor necrosis factor-alpha, IL-6, IL-10 and prostaglandin E(2). After four months of therapy, patients receiving edrecolomab demonstrated enhanced AMLR, NK, LAK activity, increased serum levels of cytokines regulating such responses and reduced levels of acute-phase cytokines and immune suppressors, compared to patients treated with conventional chemotherapy.Postoperative adjuvant therapy with edrecolomab restores the in vivo deficient immune responses of patients with resected Dukes' C CRC despite its clinical ineffectiveness in recent randomized adjuvant trials. These results suggest that further immunological studies with the combination of edrecolomab and chemotherapy are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|